GlassScriptPhysician profile
James T Chapman
NPI 1437141900
$3,915.25
in general payments reported to CMS, 2019-2025
24 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $313 · 2021: $686 · 2022: $648 · 2023: $291 · 2024: $751 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,142.54 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $687.50 | 2019-2025 | |
| Lilly USA, LLC | $296.70 | 2019-2024 | Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $283.19 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $275.73 | 2019-2024 | |
| Amgen INC. | $211.51 | 2019-2024 | Otezla |
| Pfizer INC. | $161.18 | 2024-2025 | |
| Dermavant Sciences, INC. | $156.49 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $124.11 | 2019-2023 | |
| Leo Pharma INC. | $109.16 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.20 | 2019-2022 | |
| Strata Skin Sciences, INC. | $77.34 | 2022 | |
| Genentech USA, INC. | $61.92 | 2019-2021 | |
| Janssen Biotech, INC. | $56.37 | 2020-2021 | |
| Galderma Laboratories, L.P. | $40.38 | 2024-2025 | Nemluvio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.93 | 2023 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $21.91 | 2019 | |
| Arcutis Biotherapeutics, INC. | $20.48 | 2024 | Zoryve |
| Dermira, INC. | $19.22 | 2019 | |
| Celgene Corporation | $14.74 | 2019 | |
| Vyne Pharmaceuticals INC. | $12.89 | 2020 | |
| Incyte Corporation | $12.57 | 2022 | |
| Merck Sharp & Dohme LLC | $10.88 | 2019 | |
| Organon LLC | $3.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.